Life Biosciences, co-founded by Harvard geneticist David Sinclair, received FDA approval for a Phase 1 clinical trial. The trial aims to partially reverse aging in the eye, focusing on conditions like glaucoma and NAION. This represents a significant step in the burgeoning field of longevity research, fueled by substantial investment from billionaires seeking to extend human lifespans.

This approval allows Life Biosciences to test its gene therapy on humans, potentially restoring vision. The company plans to enroll its first patients soon, with results possibly available by year-end or early next year. The company's approach involves directly injecting therapy to rejuvenate cells. This positions Life Biosciences ahead in the race to combat age-related ailments.

Life Biosciences is taking a staged approach, beginning with vision loss. The company's technology is based on research by Sinclair, focused on partial epigenetic reprogramming. The long-term goal is to extend healthy human lifespans. With fertility rates declining globally, the implications for society and the economy are substantial if this de-aging research proves successful.